StockData
Edwards Lifesciences Corp logo

Edwards Lifesciences Corp

EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3060% above fair value
$103.88−1.35 (-1.28%)

Close on Nov 19, 2026Market cap $59.88BP/E 59.7Yield –

Edwards Lifesciences Accrued Clinical Trial & Research and Development by Quarter

Accrued Clinical Trial & Research and Development Liabilities ($M)

Edwards Lifesciences Accrued Clinical Trial & Research and Development: $69.1M in Q3 2026, down 8.2% from a year earlier.

Latest, Q3 2026
69.1
Period ended Sep 30, 2026
Change on a year earlier
-8.2%
75.3 in Q3 2025
History
30 quarters
Since Q4 2018
Sources
29
Documents cited below

Where the Q3 2026 figure comes from

Source: SEC Filing (0001099800-26-000054) ↗

Reported in Form 10-K / Form 10-Q Balance Sheet & Accrued Liabilities Footnotes.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAccrued Clinical Trial & Research and Development Liabilities ($M)Year on yearSource
Q3 2026Sep 30, 202669.1-8.2%SEC Filing (0001099800-26-000054) ↗
Q2 2026Jun 30, 202669-7.3%SEC Filing (0001099800-26-000043) ↗
Q1 2026Mar 31, 202669.8-6.8%SEC Filing (0001099800-26-000026) ↗
Q4 2025Dec 31, 202569.2-6.6%SEC Filing (0001099800-26-000054) ↗
Q3 2025Sep 30, 202575.3-4.7%SEC Filing (0001099800-25-000062) ↗
Q2 2025Jun 30, 202574.4-4.6%SEC Filing (0001099800-25-000048) ↗
Q1 2025Mar 31, 202574.9-1.1%SEC Filing (0001099800-25-000023) ↗
Q4 2024Dec 31, 202474.1+3.5%SEC Filing (0001099800-26-000009) ↗
Q3 2024Sep 30, 202479+12.7%SEC Filing (0001099800-24-000086) ↗
Q2 2024Jun 30, 202478+10.3%SEC Filing (0001099800-24-000078) ↗
Q1 2024Mar 31, 202475.7+11.8%SEC Filing (0001099800-24-000039) ↗
Q4 2023Dec 31, 202371.6+7.0%SEC Filing (0001099800-25-000005) ↗
Q3 2023Sep 30, 202370.1-2.1%SEC Filing (0001099800-23-000039) ↗
Q2 2023Jun 30, 202370.7+24.0%SEC Filing (0001099800-23-000034) ↗
Q1 2023Mar 31, 202367.7+19.8%SEC Filing (0001099800-23-000021) ↗
Q4 2022Dec 31, 202266.9+14.9%SEC Filing (0001099800-24-000004) ↗

Breakdown

What makes up accrued Clinical Trial & Research and Development

Cite this data

StockData. (2026). Edwards Lifesciences Accrued Clinical Trial & Research and Development ($M), quarterly Q4 2018–Q3 2026 [Data set]. Compiled from Edwards Lifesciences SEC filings and investor materials. https://stockdatahq.com/stocks/ew/kpis/res-rd

See every metric in the Edwards Lifesciences KPI table. Data updated Nov 7, 2026.

See a number that looks wrong?